Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

CABOZANTINIB

CABOZANTINIB

Standard Dose
40MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview CABOZANTINIB is listed in Drugs@FDA under application 215942 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient CABOZANTINIB Form and strength TABLET;ORAL - 40MG Sponsor TEVA PHARMS INC Submission history Latest submission status date: 2022-10-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview CABOZANTINIB is listed in Drugs@FDA under application 215942 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CABOZANTINIB Form and strength TABLET;ORAL - 40MG Sponsor TEVA PHARMS INC Submission history Latest submission status date: 2022-10-27 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.